Stocks Overview

LAST PRICE
59.8100
TODAY'S CHANGE (%)
Trending Up0.0300 (0.0502%)

Bid / Lots
59.6200/ 2
Ask / Lots
59.9000/ 42
Open / Previous Close
59.7600 / 59.7800
Day Range
Low 59.7100
High 59.8600
52 Week Range
Low 3.6000
High 59.9500
Volume
660,102
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 59.78
Time	Volume	LBPH
09:32 ET	41779	59.8
09:33 ET	21772	59.82
09:35 ET	16447	59.77
09:37 ET	12710	59.77
09:39 ET	13509	59.76
09:42 ET	20286	59.76
09:44 ET	19516	59.75
09:46 ET	30718	59.795
09:48 ET	27206	59.71
09:50 ET	6371	59.74
09:51 ET	800	59.74
09:53 ET	1367	59.77
09:55 ET	7606	59.77
09:57 ET	4506	59.75
10:00 ET	400	59.76
10:02 ET	1093	59.75
10:04 ET	5225	59.755
10:06 ET	5477	59.77
10:08 ET	1277	59.75
10:09 ET	1977	59.75
10:11 ET	7427	59.74
10:13 ET	5921	59.75
10:15 ET	2300	59.76
10:18 ET	961	59.75
10:20 ET	6864	59.75
10:22 ET	7597	59.75
10:24 ET	2781	59.75
10:26 ET	400	59.75
10:27 ET	200	59.74
10:29 ET	400	59.75
10:31 ET	2783	59.76
10:33 ET	3482	59.77
10:36 ET	10206	59.76
10:38 ET	2423	59.75
10:40 ET	1656	59.76
10:42 ET	1378	59.75
10:44 ET	1208	59.75
10:45 ET	8475	59.76
10:47 ET	2868	59.77
10:49 ET	1594	59.76
10:51 ET	800	59.76
10:54 ET	3492	59.75
10:56 ET	5701	59.74
10:58 ET	6767	59.745
11:00 ET	4935	59.75
11:02 ET	6669	59.73
11:03 ET	1991	59.74
11:05 ET	3200	59.7499
11:07 ET	2389	59.745
11:09 ET	3255	59.75
11:12 ET	8927	59.75
11:14 ET	200	59.75
11:16 ET	200	59.75
11:18 ET	100	59.75
11:20 ET	968	59.75
11:21 ET	1687	59.75
11:23 ET	300	59.75
11:27 ET	2663	59.75
11:30 ET	595	59.75
11:32 ET	500	59.75
11:34 ET	200	59.75
11:36 ET	1567	59.75
11:38 ET	1849	59.75
11:39 ET	200	59.75
11:41 ET	700	59.75
11:43 ET	9985	59.76
11:52 ET	300	59.77
11:54 ET	100	59.77
11:56 ET	252	59.76
11:57 ET	533	59.76
11:59 ET	4762	59.79
12:01 ET	488	59.79
12:03 ET	300	59.785
12:12 ET	877	59.79
12:14 ET	100	59.795
12:15 ET	200	59.79
12:19 ET	287	59.79
12:21 ET	100	59.8
12:24 ET	1960	59.8
12:30 ET	100	59.8
12:33 ET	116	59.7991
12:35 ET	300	59.8
12:37 ET	300	59.795
12:42 ET	185	59.795
12:44 ET	200	59.8
12:46 ET	1014	59.79
12:48 ET	2684	59.79
12:53 ET	138	59.79
12:55 ET	100	59.79
12:57 ET	200	59.8
01:00 ET	100	59.8
01:02 ET	100	59.79
01:06 ET	1324	59.8
01:08 ET	100	59.8
01:09 ET	100	59.8
01:20 ET	1600	59.8
01:26 ET	488	59.795
01:27 ET	100	59.8
01:29 ET	100	59.81
01:31 ET	300	59.8
01:33 ET	100	59.81
01:36 ET	100	59.805
01:38 ET	3484	59.83
01:40 ET	218	59.83
01:42 ET	920	59.835
01:44 ET	800	59.83
01:47 ET	200	59.83
01:49 ET	200	59.83
01:51 ET	100	59.83
01:54 ET	200	59.835
01:56 ET	472	59.835
01:58 ET	100	59.835
02:02 ET	9064	59.79
02:03 ET	19844	59.795
02:05 ET	13200	59.79
02:07 ET	100	59.79
02:09 ET	1722	59.83
02:12 ET	5762	59.8
02:14 ET	436	59.81
02:18 ET	399	59.8
02:20 ET	100	59.81
02:21 ET	100	59.82
02:27 ET	100	59.82
02:30 ET	300	59.82
02:32 ET	436	59.81
02:39 ET	949	59.8
02:41 ET	379	59.81
02:43 ET	422	59.8002
02:45 ET	100	59.81
02:50 ET	1137	59.81
02:52 ET	402	59.81
02:54 ET	100	59.81
02:56 ET	132	59.81
02:57 ET	2543	59.8
02:59 ET	1374	59.81
03:01 ET	423	59.81
03:06 ET	4502	59.83
03:08 ET	750	59.83
03:10 ET	700	59.84
03:12 ET	2169	59.84
03:14 ET	1646	59.81
03:15 ET	142	59.82
03:19 ET	600	59.81
03:21 ET	100	59.82
03:26 ET	100	59.81
03:28 ET	500	59.81
03:30 ET	1523	59.81
03:32 ET	1369	59.8
03:33 ET	5547	59.8
03:39 ET	219	59.81
03:42 ET	1812	59.82
03:44 ET	1470	59.825
03:46 ET	2008	59.82
03:48 ET	100	59.82
03:50 ET	601	59.81
03:51 ET	358	59.83
03:53 ET	1943	59.82
03:55 ET	6366	59.8
03:57 ET	1244	59.8
04:00 ET	27314	59.81

Data delayed at least 15 minutes.

Nov 7, 2024
- Press Release: Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
- Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 1, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, LBPH, ZUO on Behalf of Shareholders, from 12:06PM ET on Friday Nov 01, 2024 by Dow Jones
  12:06PM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
- LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH, from 12:03PM ET on Thursday Oct 31, 2024 by Dow Jones
  12:03PM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 22, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INSI, LBPH, NBR on Behalf of Shareholders, from 11:38AM ET on Tuesday Oct 22, 2024 by Dow Jones
  11:38AM ET on Tuesday Oct 22, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesLBPH Longboard Pharmaceuticals Inc	2.3B	-27.7x	---
United StatesAKRO Akero Therapeutics Inc	2.4B	-10.1x	---
United StatesSLNO Soleno Therapeutics Inc	2.5B	-17.2x	---
United StatesBLTE Belite Bio Inc	2.5B	-66.2x	---
United StatesGPCR Structure Therapeutics Inc	2.2B	-17.0x	---
United StatesNMRA Neumora Therapeutics Inc	2.2B	-8.1x	---
As of 2024-11-10

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Contact Information

Headquarters: 4275 Executive Square, Suite 950LA JOLLA, CA, United States 92037
Phone: 619-592-9775
Fax: 302-636-5454

Executives

Independent Chairman of the Board: Paul Sekhri
President, Chief Executive Officer, Director: Kevin Lind
Chief Financial Officer, Executive Vice President: Brandi Roberts
Executive Vice President, Chief Medical Officer: Randall Kaye
Independent Director: Vincent Aurentz

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$2.3B
Revenue (TTM)	$0.00
Shares Outstanding	39.0M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.04
EPS	$-2.16
Book Value	$1.67
P/E Ratio	-27.7x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Longboard Pharmaceuticals Inc
NASDAQ:LBPHUnited States

Search Criteria

Charts

Recent News

Nov 7, 2024

Press Release: Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 1, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, LBPH, ZUO on Behalf of Shareholders, from 12:06PM ET on Friday Nov 01, 2024 by Dow Jones

Oct 31, 2024

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH, from 12:03PM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 22, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INSI, LBPH, NBR on Behalf of Shareholders, from 11:38AM ET on Tuesday Oct 22, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar